Technical evaluation of healthcare costs in insulin-dependent type 2 diabetics;Vergleichende erhebung von ressourcenverbräuchen bei typ-2-diabetes

Diabetes, Stoffwechsel und Herz

Volumn 17, Issue 6, 2008, Pages 459-465

  Schoffski O ^a   Pfohl, M ^b   Muller M ^c   Volk, M ^c   Dippel, Franz Werner ^d   Breitscheidel, L ^e   Benter, U ^e  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Evangelisches Bethesda Johanniter Klinikum   (Germany)

^c Axaris Software and Systeme GmbH   (Germany)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^e Kendle   (Germany)

Author keywords

Insulin glargin; NPH insulin; Resource utilization; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLUCOSE; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; SHORT ACTING INSULIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL EVALUATION; COMPUTER PROGRAM; DATA ANALYSIS; DRUG COST; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; INFORMATION PROCESSING; INFORMATION SYSTEM; INSULIN DEPENDENT TYPE 2 DIABETES; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OUTPATIENT; RESOURCE MANAGEMENT; RETROSPECTIVE STUDY;

EID: 57349141581     PISSN: 18617603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. von Ferber L, Köster I, Hauner H: Kosten der antihyperglykä mischen Behandlung des Diabetes mellitus - Einfluss von Lebensalter, Therapieart und Komplikationsstatus: Ergebnisse der KoDiM-Studie 2001. Med Klin 2006; 101: 384-393
2. Köster I, von Ferber L, Ihle P, Schubert I, Hauner H: The cost burden of diabetes mellitus: the evidence from Germany - the CoDiM Study. Diabetologia 2006; 49: 1498-1504
3. Hauner H, Köster I, von Ferber L: Prävalenz des Diabetes mellitus in Deutschland 1998-2001. Dtsch Med Wochenschr 2003; 128: 2632-2637
4. Icks A, Rathmann W, Rosenbauer J, Giani G; Robert-Koch-Institut (Hrsg.): Gesundheitsberichterstattung des Bundes, Heft 24: Diabetes melitus. Robert-Koch-Institut, Berlin, 2005
5. Yki-Järvinnen H, Dressler A, Ziemen M: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23: 1130-1136
6. Yki-Järvinnen H et al.: The relationship between glycemic control and hypoglycemia using insulin glargine versus NPH insulin: a metaregression analysis in type 2 diabetes (abstract). Diabetes 2003; 52: A149-A150
7. Mullins P, Sharplin P, Yki-Järvinnen H, Riddle MC, Häring HU: Negative binomial metaregression analysis of combined glycosylated haemoglobin and hypoglycaemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007; 29: 1607-1619
8. Witthaus E, Stewart J, Bradley C: Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabet Med 2001; 18: 619-625
9. Swart E, Ihle P, Geyer S, Grobe T, Hofmann W: GPS - Gute Praxis Sekundärdatenanalyse. Das Gesundheitswesen 2005; 67: 416-421
10. Hagenmeyer EG, Schädlich PK, Freytag A, Storz P, Dippel FW, Häussler B: Wirtschaftlichkeit langwirksamer Insulinanaloga bei Diabetes mellitus Typ 2 - ein systematischer Review. Perfusion 2008; 21: 157-165
11. Rathmann W, Haastert B, Riebel P, Schroeder-Bernhardi D, Kostev K, Huppertz E, Giani G: Prescription of insulin glargine in primary care practices in Germany. Exp Clin Endocrinol Diabetes 2007; 115: 252-256
12. Janka HU, Högy B: Pharmakoökonomische Aspekte der Therapie des Typ-2-Diabetes mit Insulin glargin auf Basis der LAPTOP-Studie. Eur J Health Econ 2008; 9: 165-170